Cell man­u­fac­tur­ing com­pa­ny rais­es $19M Se­ries A to in­crease ca­pac­i­ty, staff num­bers 

A Lon­don-based start­up that builds ma­chines that con­vert stem cells in­to more spe­cif­ic cell types has closed a $19 mil­lion Se­ries A round to boost its pro­duc­tion ca­pac­i­ty and in­crease its team of 30 staff mem­bers to 50.

My­tos is cur­rent­ly “at the lim­it” of how fast it can build its ma­chines, CEO Ali Af­shar told End­points News in an in­ter­view. And the Se­ries A is de­signed to in­crease the build and dis­tri­b­u­tion of its cell pro­duc­tion sys­tem — sim­ply named the My­tos Plat­form — and grow its sales and de­vel­op­ment work­force.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER